In a nutshell Ampio has had a struggle to success, not by pharmaceutical terms but by the market’s ability to manipulate small companies for the benefit of others. The ability to facilitate hard swings gives shorters the edge to make a quick profit by publicizing news that is intentionally negatively misleading. Ampio has suffered its share of misleading information by shorters but as the time is drawing near to the end of trials, beginnings of others and a potential profit from Zertane the battleground is starting to shift. In my opinion as a long time pharmaceutical investor and long position holder with Ampio, I agree with the latest article that Ampio holds a huge potential, low risk and tremendous upside investment. Please do your own research but I think you will find Ampio has the ability, pipeline, staff and money to provide a healthy return for the serious investor. PCYC provided the same return and made wealthy people over the last year, although I feel PCYC is reaching the summit Amphio will be the next climber in line to the top. For disclosure I am a lifelong pharmaceutical investor, currently long on AMPE, PCYC, and just for a wildcard FSLR.